Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27970605 | 0.85 | MAPK8 (0.39) | MAPK8RPS6KB1MAOBPARP10GRM2 | |
| SCHEMBL11901445 | 0.84 | PLA2G2A (0.46) | ALDH1A1LMNA | |
| SCHEMBL7844303 | 0.80 | MAPK8 (0.40) | MAPK8RPS6KB1MAOBPARP10ALDH1A1 | |
| SCHEMBL28974830 | 0.78 | MAPT (0.40) | MAPK8RPS6KB1MAOBPARP10ALDH1A1 | |
| SCHEMBL27895663 | 0.76 | RPS6KB1 (0.46) | MAPK8RPS6KB1MAOBPARP10ALDH1A1 | |
| SCHEMBL1500536 | 0.74 | TSHR (0.51) | MAPK8RPS6KB1GRM2HSP90AA1ALDH1A1 | |
| SCHEMBL5550700 | 0.74 | PLA2G2A (0.45) | ALDH1A1 | |
| SCHEMBL28658004 | 0.71 | RPS6KB1 (0.42) | MAPK8RPS6KB1MAOBPARP10ALDH1A1 | |
| SCHEMBL9018997 | 0.70 | KMT2A (0.39) | ALDH1A1LMNA | |
| SCHEMBL5802389 | 0.69 | PLA2G2A (0.46) | MAPK8PARP10LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501992-B2 | Hydroxyphenyl sulfonamides as antiapoptotic bcl inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2297103-B1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| EP-2297103-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009152082-A1 | HYDROXYPHENYLSULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294793-A1 | HYDROXYPHENYL SULFONAMIDES AS ANTIAPOPTOTIC BCL INHIBITORS | BCL2, BAX, BCL2A1 | MAPK8 2421/4885RPS6KB1 1711/4885MAOB 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.